Kazia Therapeutics (KZIA) Stock Forecast & Price Target

Kazia Therapeutics is viewed positively because paxalisib is showing an unusually differentiated clinical profile, with an 83% ORR and 100% CBR in six evaluable metastatic TNBC patients, including a complete response and CNS activity, while also avoiding paxalisib-related serious adverse events and grade 3+ hyperglycemia, stomatitis, or mucositis. Its appeal is strengthened by a biomarker-rich mechanism that may suppress CTC clusters, restore exhausted CD8+ T cells, and potentially reprogram tumors through PI3K/mTOR plus epigenetic and inflammatory effects, which could improve odds of success in TNBC, HR+/HER2- breast cancer, GBM, and pediatric brain tumors. The investment case is further supported by a broadening development path, including Arm B expansion from 12 to 36 patients, about $46M in cash, and projected peak paxalisib sales of roughly $500M to $580M, with TNBC as the main driver.

Kazia Therapeutics is viewed pessimistically because its lead Paxalisib program remains highly dependent on uncertain clinical execution, with the Arm B expansion failing to show adequate response rates or a compelling PFS profile, which cuts projected TNBC sales to about $200 million and implies only a 25% probability of success. The company also faces major regulatory, commercial, and manufacturing risks, including the possibility of no approval even after pivotal trial success, intense TNBC competition, and reliance on third-party CDMOs that could delay trials or commercial supply. While GBM offers long-term optionality, newly diagnosed MGMT-unmethylated GBM is a highly resistant indication, and the company’s long-dated DCF model out to 2043 underscores how far future value depends on uncertain outcomes.